The future of drug-eluting stents

Pharmacological Research

Volumn 57, Issue 3, 2008, Pages 171-180

  Kukreja, Neville ^a   Onuma, Yoshinobu ^a   Daemen, Joost ^a   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angioplasty; Drug eluting stent; Polymer

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BEVACIZUMAB; BIOLIMUS; CLOPIDOGREL; DEXAMETHASONE; ESTRADIOL; EVEROLIMUS; GENISTEIN; HEPARIN; PACLITAXEL; PIMECROLIMUS; POLYGLACTIN; POLYLACTIC ACID; POLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; STAINLESS STEEL; TACROLIMUS; TICLOPIDINE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

BIOCOMPATIBILITY; BIODEGRADABLE IMPLANT; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DRUG BINDING; DRUG ELUTING STENT; DRUG RELEASE; HUMAN; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MATERIAL COATING; MEDICAL PRACTICE; MEDICAL RESEARCH; METAL IMPLANTATION; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; RISK MANAGEMENT; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; ANIMALS; ANTICOAGULANTS; CORONARY RESTENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; METALS;

EID: 41549144234     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.01.012     Document Type: Review

References (103)

1. Cook S., Togni M., Walpoth N., Maier W., Meuhlberger V., Legrand V., et al. Percutaneous coronary interventions in Europe 1992-2003. EuroIntervention 1 (2006) 374-379
2. Morice M.-C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., et al., the RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
3. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T., Kinnaird T., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1519-1521
4. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
5. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
6. Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1 (1978) 263
7. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 1979;301:61-8.
8. Sigwart U., Puel J., Mirkovitch V., Joffre F., and Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 316 (1987) 701-706
9. Serruys P.W., de Jaegere P., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., et al., The Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 331 (1994) 489-495
10. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., et al., The Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 331 (1994) 496-501
11. Weintraub W.S. The pathophysiology and burden of restenosis. Am J Cardiol: Med Breakthroughs Restenosis Prev 100 (2007) S3-S9
12. Schomig A., Neumann F.-J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 (1996) 1084-1089
13. Bertrand M.E., Rupprecht H.-J., Urban P., Gershlick A.H., and f. t. C. Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102 (2000) 624-629
14. Rajagopaland V., and Rockson S.G. Coronary restenosis: a review of mechanisms and management. Am J Med 115 (2003) 547-553
15. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., et al., the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
16. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al., the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 350 (2004) 221-231
17. Stone G.W., Ellis S.G., Cannon L., Mann J.T., Greenberg J.D., Spriggs D., et al., for the TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
18. Serruys P.W., Ong A.T.L., Morice M.-C., De Bruyne B., Colombo A., Macaya C., et al. Arterial revascularisation therapies study part II - sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention 1 (2005) 147-156
19. Ong A.T., van Domburg R.T., Aoki J., Sonnenschein K., Lemos P.A., and Serruys P.W. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 47 (2006) 1356-1360
20. Daemen J., Ong A.T., Stefanini G.G., Tsuchida K., Spindler H., Sianos G., et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol 98 (2006) 895-901
21. Daemen J., and Serruys P.W. Drug-eluting stent update 2007. Part II: unsettled issues. Circulation 116 (2007) 961-968
22. Finn A.V., Nakazawa G., Joner M., Kolodgie F.D., Mont E.K., Gold H.K., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
23. Marxand S.O., and Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 (2001) 852-855
24. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351 (2004) 2715-2729
25. Sousa J.E., Costa M.A., Abizaid A., Abizaid A.S., Feres F., Pinto I.M.F., et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103 (2001) 192-195
26. Schofer J., Schluter M., Gershlick A.H., Wijns W., Garcia E., Schampaert E., et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
27. Schampaert E., Cohen E.A., Schluter M., Reeves F., Traboulsi M., Title L.M., et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 (2004) 1110-1115
28. Lemos P.A., Serruys P.W., van Domburg R.T., Saia F., Arampatzis C.A., Hoye A., et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 109 (2004) 190-195
29. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 1030-1039
30. Spaulding C., Daemen J., Boersma E., Cutlip D.E., and Serruys P.W. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356 (2007) 989-997
31. Steffel J., Latini R.A., Akhmedov A., Zimmermann D., Zimmerling P., Luscher T.F., et al. Rapamycin, but not FK-506. Increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation 112 (2005) 2002-2011
32. Imanishi T., Kobayashi K., Kuki S., Takahashi C., and Akasaka T. Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis 189 (2006) 288-296
33. Muldowney III J.A., Stringham J.R., Levy S.E., Gleaves L.A., Eren M., Piana R.N., et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27 (2007) 400-406
34. Hofma S.H., van der Giessen W.J., van Dalen B.M., Lemos P.A., McFadden E.P., Sianos G., et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J 27 (2006) 166-170
35. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., et al., for the TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based. paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
36. Ong A.T., Serruys P.W., Aoki J., Hoye A., van Mieghem C.A., Rodriguez-Granillo G.A., et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 45 (2005) 1135-1141
37. Grube E., Dawkins K.D., Guagliumi G., Banning A.P., Zmudka K., Colombo A., et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 28 (2007) 2578-2582
38. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.-C., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
39. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
40. Stahli B.E., Camici G.G., Steffel J., Akhmedov A., Shojaati K., Graber M., et al. Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res 99 (2006) 149-155
41. Schuler W., Sedrani R., Cottens S., Haberlin B., Schulz M., Schuurman H.J., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64 (1997) 36-42
42. Grube E., Sonoda S., Ikeno F., Honda Y., Kar S., Chan C., et al. Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 109 (2004) 2168-2171
43. Serruys P.W., Ong A.T.L., Piek J.J., Neumann F.-J., van der Giessen W.J., Wiemer M., et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1 (2005) 58-65
44. Tsuchida K., Piek J.J., Neumann F., van der Giessen W.J., Wiemer M., Zeiher A., et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). EuroIntervention 1 (2005) 266-272
45. Serruys P.W., Ruygrok P., Neuzner J., Piek J.J., Seth A., Schofer J.J., et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2 (2006) 286-294
46. Beijk M.A., Neumann F.J., Wiemer M., Grube E., Haase J., Thuesen L., et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial). EuroIntervention 3 (2007) 206-212
47. Meredith I.T., Ormiston J.A., Whitbourn R., Kay P., Muller D., Bonan R., et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: endeavor I trial. EuroIntervention 1 (2005) 157-164
48. Kandzari D.E., Leon M.B., Popma J.J., Fitzgerald P.J., O'Shaughnessy C., Ball M.W., et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 48 (2006) 2440-2447
49. Fajadet J., Wijns W., Laarman G.-J., Kuck K.-H., Ormiston J., Munzel T., et al., for the ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114 (2006) 798-806
50. Miyazawa A., Ako J., Hongo Y., Hur S.-H., Tsujino I., Courtney B.K., et al. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. Am Heart J 155 (2008) 108-113
51. Jain A.K., Meredith I.T., Lotan C., Rothman M.T., and Pateraki S. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-five registry. Am J Cardiol: Integr Safe Pract Drug-Eluting Stent Deployment 100 (2007) S77-S83
52. Mehta R.H., Leon M.B., and Sketch Jr. M.H. The Relation between clinical features, angiographic findings, and the target lesion revascularization rate in patients receiving the endeavor zotarolimus-eluting stent for treatment of native coronary artery disease: an analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II continued access registry, and ENDEAVOR III. Am J Cardiol: Integr Safe Pract Drug-Eluting Stent Deployment 100 (2007) S62-S70
53. Meredith I.T., Ormiston J., Whitbourn R., Kay I.P., Muller D., Popma J.J., et al. Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study. Am J Cardiol: Integr Safe Pract Drug-Eluting Stent Deployment 100 (2007) S56-S61
54. Mauri L., Hsieh W.-h., Massaro J.M., Ho K.K.L., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
55. Stettler C., Wandel S., Allemann S., Kastrati A., Morice M.C., Schomig A., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
56. Finn A.V., Joner M., Nakazawa G., Kolodgie F., Newell J., John M.C., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
57. Lagerqvist B., James S.K., Stenestrand U., Lindback J., Nilsson T., Wallentin L., and the SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
58. Kuchulakanti P.K., Chu W.W., Torguson R., Ohlmann P., Rha S.-W., Clavijo L.C., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
59. Park D.-W., Park S.-W., Park K.-H., Lee B.-K., Kim Y.-H., Lee C.W., et al. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
60. Okabe T., Mintz G.S., Buch A.N., Roy P., Hong Y.J., Smith K.A., et al. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 100 (2007) 615-620
61. Win H.K., Caldera A.E., Maresh K., Lopez J., Rihal C.S., Parikh M.A., et al., for the EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009
62. Farb A., Burke A.P., Kolodgie F.D., and Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 108 (2003) 1701-1706
63. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
64. Awata M., Kotani J.-i., Uematsu M., Morozumi T., Watanabe T., Onishi T., et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 116 (2007) 910-916
65. Kotani J.-i., Awata M., Nanto S., Uematsu M., Oshima F., Minamiguchi H., et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 47 (2006) 2108-2111
66. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serruys P.W., Holmes Jr. D.R., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 (1996) 1690-1697
67. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
68. Nebeker J.R., Virmani R., Bennett C.L., Hoffman J.M., Samore M.H., Alvarez J., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 (2006) 175-181
69. Kastrati A., Mehilli J., Dirschinger J., Dotzer F., Schuhlen H., Neumann F.-J., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103 (2001) 2816-2821
70. Pache J.U., Kastrati A., Mehilli J., Schuhlen H., Dotzer F., Hausleiter J.O., et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 41 (2003) 1283-1288
71. Aoki J., Ong A.T.L., Abizaid A., Heijer P.d., Bonnier H., McClean D.R., et al. One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer-insight in the paclitaxel in-stent controlled elution study (PISCES). EuroIntervention 1 (2005) 165-172
72. Serruys P.W., Sianos G., Abizaid A., Aoki J., den Heijer P., Bonnier H., et al. The Effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the paclitaxel in-stent controlled elution study (PISCES). J Am Coll Cardiol 46 (2005) 253-260
73. Ormiston J.A., Webster M.W.I., Jack S.E., Ruygrok P.N., Stewart J.T., Scott D., et al. Drug-eluting stents for coronary bifurcations: bench testing of provisional side-branch strategies. Catheter Cardiovasc Interv 67 (2006) 49-55
74. Grube E., Buellesfeld L., Neumann F.J., Verheye S., Abizaid A., McClean D., et al. Six-month clinical and angiographic results of a dedicated drug-eluting stent for the treatment of coronary bifurcation narrowings. Am J Cardiol 99 (2007) 1691-1697
75. Abizaid A.C., De Ribamar Costa J., Whitbourn R.J., and Chang J.C. The CardioMind coronary stent delivery system: stent delivery on a 014" guidewire platform. EuroIntervention 3 (2007) 154-157
76. Evans L.W., Doran P., and Marco P. XTENT® custom NX™ drug eluting stent systems. EuroIntervention 3 (2007) 158-161
77. Ge J., Qian J., Wang X., Wang Q., Yan W., Yan Y., et al. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter Cardiovasc Interv 69 (2007) 198-202
78. Lee C.H., Lim J., Low A., Zhang X.L., Kyaing T.T., Chan M.Y., et al. Sirolimus-eluting, bioabsorbable polymer-coated constant stent (Cura) in acute ST-elevation myocardial infarction: a clinical and angiographic study (CURAMI Registry). J Invasive Cardiol 19 (2007) 182-185
79. Vranckx P., Serruys P.W., Gambhir S., Sousa E., Abizaid A., Lemos P., et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium™ stent: 9-month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2 (2006) 310-317
80. Windecker S., Simon R., Lins M., Klauss V., Eberli F.R., Roffi M., et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 111 (2005) 2617-2622
81. Wessely R., Hausleiter J., Michaelis C., Jaschke B., Vogeser M., Milz S., et al. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 25 (2005) 748-753
82. Mehilli J., Kastrati A., Wessely R., Dibra A., Hausleiter J., Jaschke B., et al., for the Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between 2 Drug-Eluting Stents (ISAR-TEST) Trial Investigators. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113 (2006) 273-279
83. Rajtar A., Kaluza G., Yang Q., Hakimi D., Liu D., Tsui M., Lien M., Smith D., Clubb Jr. F.J., and Troczynski T. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2 (2006) 113-115
84. Kollum M., Farb A., Schreiber R., Terfera K., Arab A., Geist A., et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 64 (2005) 85-90
85. Grube E., Hauptmann K.-E., Buellesfeld L., Lim V., and Abizaid A. Six-month results of a randomized study to evaluate safety and efficacy of a biolimus A9 eluting stent with a biodegradable polymer coating. EuroIntervention 1 (2005) 53-57
86. Costa R.A., Lansky A.J., Abizaid A., Mueller R., Tsuchiya Y., Mori K., et al. Angiographic results of the first human experience with the biolimus A9 drug-eluting stent for de novo coronary lesions. Am J Cardiol 98 (2006) 443-446
87. Chevalier B., Serruys P.W., Silber S., Garcia E., Suryapranata H., Hauptmann K., et al. Randomised comparison of Nobori™, biolimus A9-eluting coronary stent with a Taxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the Nobori 1 trial. EuroIntervention 2 (2007) 426-434
88. Mohacsi P.J., Tuller D., Hulliger B., and Wijngaard P.L. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet-derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 16 (1997) 484-492
89. Matter C.M., Rozenberg I., Jaschko A., Greutert H., Kurz D.J., Wnendt S., et al. Effects of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol 48 (2006) 286-292
90. Morice M.-C., Bestehorn H.-P., Carrie D., Macaya C., Aengevaeren W., Wijns W., et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2 (2006) 45-52
91. Tanimoto S., van der Giessen W., van Beusekom H., Sorop O., Kukreja N., Fukaya K., et al. MAHOROBA™: Kaneka's tacrolimus eluting coronary stent. EuroIntervention 3 (2007) 149-153
92. Aoki J., Serruys P.W., van Beusekom H., Ong A.T.L., McFadden E.P., Sianos G., et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) registry. J Am Coll Cardiol 45 (2005) 1574-1579
93. Duckers H.J., Silber S., Winter R.d., Heijer P.D., Rensing B., Rau M., et al. Circulating endothelial progenitor cells predict angiographic and intravascular ultrasound outcome following percutaneous coronary interventions in the HEALING-II trial: evaluation of an endothelial progenitor cell capturing stent. EuroIntervention 3 (2007) 67-75
94. Duckers H.J., Soullié T., Heijer P.d., Rensing B., Winter R.J.d., Rau M., et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final results of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent)™. EuroIntervention 3 (2007) 350-358
95. Co M., Tay E., Lee C.H., Poh K.K., Low A., Lim J., et al. Use of endothelial progenitor cell capture stent (Genous Bio-Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial infarction: Intermediate- to long-term clinical follow-up. Am Heart J 155 (2008) 128-132
96. Stefanadis C., Toutouzas K., Stefanadi E., Kolodgie F., Vermani R., and Kipshidze N. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic J Cardiol 47 (2006) 7-10
97. Tamai H., Igaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., et al. Initial and 6-month results of biodegradable poly-l-lactic acid Coronary stents in humans. Circulation 102 (2000) 399-404
98. Tanimoto S., Serruys P.W., Thuesen L., Dudek D., Bruyne B.d., Chevalier B., et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 70 (2007) 515-523
99. Kukreja N., Otsuka M., van Mieghem C., Ligthart J., Sianos G., and Serruys P. Biodegradable drug eluting stents: invasive and non-invasive imaging. EuroIntervention 2 (2006) 403
100. Eggebrecht H., Rodermann J., Hunold P., Schmermund A., Bose D., Haude M., et al. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 112 (2005) e303-e304
101. Bose D., Eggebrecht H., and Erbel R. Absorbable metal stent in human coronary arteries: imaging with intravascular ultrasound. Heart 92 (2006) 892
102. Erbel R., Di Mario C., Bartunek J., Bonnier J., de Bruyne B., Eberli F.R., et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369 (2007) 1869-1875
103. van Beusekom H.M., Saia F., Zindler J.D., Lemos P.A., Swager-Ten Hoor S.L., van Leeuwen M.A., et al. Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J 28 (2007) 974-979